Internet Virtual Exhibition for Life Science Industry

Almac Sciences

CDMO

Business Category : Drug Substance, Drug Additives, Intermediate、CMO、Contract Service- Analysis & test 、Pharmaceutical manufacturing、Chemical product manufacturing

Main Service Region : Japan、United States、Korea, Republic of、Taiwan、Europe(excluding UK)、United Kingdom

<%=SectionAbout%>

News Releases

    <%=SectionNews%>

Products & Services

2022/06/23

API Manufacturing

API

API Development & Manufacture

 

Our technical expertise and extensive facilities enable us to offer integrated API contract manufacturing solutions through all stages of the drug development lifecycle. We are fully supported by dedicated analytical and regulatory teams.

We offer numerous support capabilities, including:
• rapid implementation of chromatography for purification
• containment equipment for potent compounds
• micronisation to control particle size

Our dynamic team successfully address many complex project challenges, and implementing our on-site biocatalysis technology expertise is one example of our responsive solutions.

Early clinical phase

We have significant experience in the first time scale-up of APIs. Starting with the medicinal chemistry route, our knowledgeable chemists can quickly identify the most pressing parts of the chemistry to develop. Our chemists work closely with our development analysts and production teams to ensure that controls are appropriately embedded into the process IPCs, intermediate specifications and processing instructions. The salt form and polymorph landscape are explored within our physical sciences teams and drive the development of the API isolation process. Particle size is controlled through our micronisation suite.

Late clinical phase

We have an established reputation for developing processes for late clinical stage. Our extensive experience lies in taking processes from inception through to process validation, both in small molecule chemistry and peptides. As an API moves from early clinical phase towards late clinical phase, the emphasis of the project changes. Whereas in early clinical supply, a lean fit-for-purpose approach is appropriate, other factors start to dominate when moving towards late phase, particularly process efficiency and knowledge. We strategically integrate the principles from regulatory guidelines (FDA, ICH, USP), such as risk management and quality by design, as a basis for development and manufacturing strategies.

Highly potent manufacture

We have responded to the growing need for manufacture and handling highly potent compounds, including cytotoxics, in a dedicated and separate contained manufacturing suite. Our evaluation process begins with a thorough review of current knowledge of both the API and intermediates, including the appropriate health and safety, toxicology and operations experts. Comparison to known compounds is used and additional testing is carried out where necessary. Clear SOPs and operating instructions are generated based on this thorough review. We are one of the first companies in Europe to receive SafeBridge certification. Our containment and isolation facilities allow the handling of compounds with OELs down to 0.1 μg / m3. We use isolators in a GMP Class 100,000 facility, featuring pressurised anti-rooms, door interlocks and separate equipment and personnel movement.

 

Why choose Almac for API development & manufacture?

Our reputation and strength in API development and manufacture precedes us within pharma and biotech companies who seek integrated drug development solutions from molecule to market. Our technical expertise and extensive facilities enable us to offer integrated API contract manufacturing, on one site through all stages of the drug development lifecycle. Complementing our API services, we support a world leading biocatalysis platform to secure the supply of biocatalysts for non-GMP and GMP manufacturing projects alike. Additionally our services are supported by specialist departments, including 14C radiolabelling, preformulation, solid state services and analytical support, ensuring the needs of your drug development programme are fully met whilst maintaining our track record of saving time and cost.

 

“We retain our business with Almac because their technical approach, expertise and communication through project management cannot be matched.”

Client testimonial

 

More Details

2022/06/23

Peptide & Protein Technology

API

Almac’s Peptide and Protein Technology (PPT) group has been manufacturing peptides for the research community and clinical trials development since 1994. We place significant emphasis on peptide synthesis methodology and have manufactured well over 10,000 peptides for the research community. Focussing on the delivery of high quality products, we have developed a highly differentiated skill set allowing us to tackle challenging projects such as long peptides (>100mers), macrocyclics and conjugates.

Almac has two UK-based sites. Our site in Edinburgh, Scotland focuses on high throughput manufacture for non-GMP research use, and our global HQ site in Craigavon, Northern Ireland on cGMP manufacture.

 

Non-GMP custom synthesis

Our high throughput, non-GMP group uses the latest peptide manufacturing methodology and equipment for the rapid custom manufacture of peptides for researchers across the globe. Whether the supply of a single peptide for a one-off experiment, or the manufacture of hundreds of peptides for protein mapping, or a clinical lead generation programme, Almac can deliver. Our service is totally customised and we can manufacture peptides that are linear or cyclised, standard or modified, on the milligram to gram scale.

 

“We’ve been working with this molecule for nearly 15 years, and still Almac taught us things about it we didn’t already know.”

Client testimonial

 

We can incorporate the full range of modifications to your peptide sequence:
Probes such as biotin or fluorophores
Cyclised peptides: macrocyclic, side-chain stapling, single or multiple disulphide bridges
Post-translational modifications such as methylations, phosphorylation and glycosylation

Even in the simplest of projects, Almac will keep the client aware of progress in the manufacture, as well as delivery, so that the client can effectively plan experiments.

Conjugation expertise

Almac has a long standing interest, and over 15 years’ experience, in the art of conjugation. Increasingly, chemistry is called upon to join peptides to proteins or other moieties such as fatty acids or PEGs in order to impart favourable qualities such as stability, receptor targeting or half-life extension. In particular, we enjoy a successful collaboration with Albumedix in conjugation of peptides with albumin through their VeltisR platform.

Almac has experience in a wide variety of conjugation chemistries to ensure control and selectivity:
Thiol – maleimide
Thiol – bromoalkyl
Thiol – thioester (native chemical ligation)
Amine – NHS
Alkyne – azide (“click” chemistry)
Aminooxy – aldehyde
Hydrazide – aldehyde

Specialist catalogue reagents

Almac also provides a range of specialist catalogue products for use in basic research. These reagents are available from stock and shipped within 24 hours of ordering.
 

Chemokines (wild type, biotin, AlexaFluor® 647 labelled):

Chemokines are a family of cytokines comprising 70-80 amino acids, and containing two or more disulphide bridges. They are involved with immune responses and implicated with a range of therapeutic areas such as inflammation, oncology and anti-virals.

 

Histones: This family of proteins are 120-150 amino acids in length, with high degrees of post translational modifications including Lys/Arg methylations and Ser phosphorylations. Histones are involved with packaging DNA into structural units (nucleozomes), and the reagents are used to investigate wide ranging enzymatic activity.

Ubiquitins: Ubiquitin binds to a range of substrate proteins to mark them for degradation or affect their activity through surface Lys or Cys residues. We have a range of ubiquitylated substrates to act as probes investigating enzymatic pathways.

Almac has over 60 wild type and modified chemokines, 20 histone and ubiquitin reagents available from stock, and is also able to provide custom synthesis of bespoke reagents.

 

GMP peptide manufacture

Almac has been manufacturing GMP peptides since 2007, and has a strong reputation for expertise and service delivery. Our client base is derived across the academic, biotech and pharma sectors through Europe, North America and Asia. All our cGMP projects benefit from support from our experienced project management, analytical and quality assurance functions.

 

First in human

We have manufactured numerous peptide drug substances for First in Human trials. The package provided can be tailored according to the experiences and needs of the client. Whatever the content, the aim of the package is to ensure that material is provided for the first patients quickly, and under cGMP control. We ensure robust process development techniques are used to define an appropriate manufacturing process for each peptide and we are experienced in defining new processes, or in transferring in existing processes. We have helped multiple SME clients who have since licensed their projects to large pharma, with Almac continuing supply.

 

Peptide vaccine cocktails

An increasingly popular approach is to use multiple peptides in therapeutic vaccines in fields such as oncology and anti-allergy. Such approaches involve the manufacture of multiple peptide drug substances which are combined in a drug product cocktail for use as a vaccine. Cocktails present multiple technical and logistical challenges which Almac is experienced in overcoming through the delivery of multiple projects.

 

Late phase and commercial

Almac is also experienced at delivering late phase clinical programs towards commercial manufacture. Here the focus is in ensuring a strong understanding of the parameters influencing variation within a manufacturing process and in delivering cost of goods targets. We follow industry guidelines on process validation, utilising modern Quality by Design methods. The key here is to build a full understanding of the manufacturing process, analytical methods, facilities qualification and cleaning procedures. We achieve this through our bespoke Process Validation Roadmap.

 

NeoPeptidesTM

NeoPeptidesTM are peptides which originate from tumour derived mutations (neoantigens) and are manufactured for incorporation into personalised cancer vaccines. The field of personalised cancer vaccines requires a new manufacturing paradigm to ensure rapid, high throughput manufacture of multiple NeoPeptidesTM to the appropriate quality and regulatory standards required for a clinical setting. The manufacturing methods and quality system required vary greatly from conventional API manufacture, and Almac has for several years been tailoring process accordingly. We have used our years of experience in the field to define robust manufacturing methods designed specifically for the manufacture of NeoPeptidesTM. Such methods have been implemented in the manufacture of multiple patient sets for use in clinical trials. More recently, an entirely bespoke quality system has been written to support our newly constructed dedicated GMP facility for NeoPeptideTM manufacture. The requirements for each client are different, and Almac has experience of operating within a wide range of parameters. We can also provide support for IND application and have experience of supporting sponsor submissions to a range of regulatory authorities across the globe.

 

Why choose Almac for peptides?

Almac has developed a reputation for sound technical capability and excellent customer relations skills. We achieve these capabilities through structured knowledge management and a culturally embedded project management philosophy bringing together multidisciplinary teams for drug substance manufacturing programmes. Our highly motivated teams work tirelessly to deliver projects to customer requirements.

 

“We found the methodology Almac used to transferthe process to their facility was really well structured. We’ve started to use the same approach for our internal projects.”

Client testimonial

More Details

2022/06/23

Analytical Services

Analysis

From our state-of-the-art FDA and MHRA audited laboratories in the UK, Europe and US, we employ over 150 highly trained analytical scientists with expertise in all areas of drug development, including small molecules, peptides, conjugates and potent materials. Our European laboratory is Ireland’s leading GMP, GLP (INAB) and GCP analytical support provider and fully certified contract laboratory.

Drawing upon our vast pool of scientific knowledge, we can greatly reduce the analytical challenges that typically arise during drug development.

Utilising a wide range of instrumentation, Almac will deliver fit-for-purpose solutions to match your analytical requirements.

Clients who use Almac to release drug substance and drug product in the EU and US benefit from shortened transfer time, cost savings and minimized disruption thanks to scientific and procedural continuity. Almac is unmatched in its ability to manufacture clinical trial supplies and provide analytical support.

 

“Almac’s Analytical Team continually demonstrate that we can rely on their services and timelines as promised.”

Client Testimonial

 

 

Why choose Almac for analytical services? 

Communication and scientific continuity and key, whether your analytical requirements are stand-alone or form part of a drug development or commercial manufacture project. Our analytical scientists work with our drug substance and drug product formulation scientists, forming an integral part of the project team. This means they can share data, easily coordinate planning and scheduling, and deliver maximum efficiency.

 

More Details

2022/06/23

Solid State Services

API

Our Physical Sciences group unites chemists, analysts and formulators in one team, adding value through synergy. They have a considerable breadth of expertise in form screening and selection, so they can skilfully guide you to make the right decisions at the right time.

We develop and validate processes and methods to control and deliver the desired form during scale-up, troubleshoot existing problems and provide support for your intellectual property.

Our highly skilled scientists have undertaken thousands of studies that range from routine analysis to challenging characterisation under GMP studies.

 

 

formufastTM for Early Enabling formulations

Often drug candidates can exhibit poor bioavailability in early animal studies, which cannot always be overcome by traditional salt formation or particle size reduction strategies. Developing a strong understanding early in drug development is key to preventing common reasons for failure and producing enabling formulations to maximise outcomes. Our early formulation platform, formufastTM, allows rapid, tailored screening of small quantities of API against a range of excipients.

 

Advantages of formufastTM screening include:

• Rapid identification of potential bioavailability issues
• Tailored approaches to overcome specific compound challenges
• Rational formulation approaches to achieve optimal outcomes
• In depth understanding of formulation effects and in vivo prediction
• Delivering the maximum information from small quantities of compound

 

Why choose Almac for solid state services?

We are experts in solid state chemistry. We understand that identifying and consistently producing a drug in its optimal physical form is vital to the success of drug development programmes, and we ensure our services are specifically tailored to our clients’ needs. We have a proven track record with >150 virtual, biotech and large pharma clients in screening, troubleshooting and providing analytical solutions spanning the entire drug lifecycle.

 

“Given their expertise in drug substance and drug product development, Almac’s Physical Sciences Team were especially well positioned to identify physical forms that may give rise to valuable sources of intellectual property.”

Client testimonial

More Details

2022/06/23

14C Radiolabelling

API

We provide industry-leading 14C labelled drug substance and drug product services to meet your quality, cost and delivery expectations. With our extensive experience in the synthesis and analysis of stable and 14C isotope labelled compounds, we can label any compound from simple molecules to complex structures including small molecules, peptides and bio conjugates, in our MHRA approved facilities.

 

14C is the radioisotope of choice in preclinical and clinical ADME studies, avoiding the challenges encountered with tritium labelling such as label exchange and the loss of label due to radioactive decay.

Isotopic labelling imposes many synthetic challenges beyond those found in normal chemical synthesis, and when the isotope is radioactive this adds further safety and regulatory requirements. By choosing Almac as your isotope labelling provider you will have access to our wealth of experience in both stable- and radio-labelled synthesis.

We provide a complete suite of solutions for your needs, including: non-GMP and GMP radiolabelling / stable labelling, bio conjugate labelling, quality control and analytical support (including method development, validation / transfer and stability studies), storage and repurification.

 

Why choose Almac for 14C radiolabelling?

Our proven track record in synthesis and purification, coupled with our seamless analytical and QC integration, ensures your labelled product will be manufactured with the desired chemical and radiochemical purity and rigorously analysed using validated equipment. Our strong quality culture will ensure the material manufactured will satisfy the requirements of the relevant regulatory authority.

 

“I was very impressed by the planning and execution by the Almac 14C team in the GMP synthesis of our target. Timelines and goals were met. The team also showed flexibility to respond to our ever changing needs”

Client testimonial

More Details

2022/06/23

Biocatalysis

API

Almac is recognised globally as a key player in the area of biocatalyst research, development and commercial supply of biocatalytically derived achiral and chiral products at multi-tonne scale. Our expertise ranges from enzyme discovery, engineering and screening to the enzyme applied synthesis of complex chiral products, all based on Almac’s selectAZymeTM technology.

 

Almac has an established platform technology for the secure supply of selectAZymeTM biocatalysts for clients’ non-GMP and GMP manufacturing projects. Biocatalysts are now essential tools in chemical synthesis and offer a direct and simple way to synthesise complex achiral and chiral compounds.

Our exclusive selectAZymeTM technology platform consists of multiple recombinant enzyme panels that can be used in chemical processing across multiple functional group interchanges. Enzymes can offer attractive new synthetic routes to compounds and can deliver best-in-class synthesis that offer many advantages over traditional chemistry, such as lower waste, fewer processing steps, high purity and lower cost.

 

 

Why choose Almac for biocatalysis?

We can help take your project from conception to scale-up.
Our biocatalysis group consists of computational, molecular and microbiologists, enzymologists, organic chemists and analysts, and have demonstrated expertise in in gene identification, expression, enzyme evolution, fermentation, enzyme production and biotransformation scale-up.
Our team is closely linked to the process chemistry and manufacturing chemistry groups, where enzyme discovery and development is integrated with screening and route definition. Each member of the team brings expertise to complex processes and procedures and can rapidly implement an enzymatic process to significantly improve the yield and timelines of a multistep synthesis.

 

“I can fully recommend Almac as a partner of choice in the area of bio-processing, enzyme immobilisation and chemistry scale-up.”

Client testimonial

More Details

Campaigns

<%=SectionCampaign%>

Seminars

<%=SectionSeminar%>

White Papers

<%=SectionWhite%>